keyword
MENU ▼
Read by QxMD icon Read
search

infliximab level

keyword
https://www.readbyqxmd.com/read/29232322/incidence-of-antidrug-antibodies-in-rheumatoid-arthritis-patients-from-argentina-treated-with-adalimumab-etanercept-or-infliximab-in-a-real-world-setting
#1
Pablo J Maid, Ricardo Xavier, Rosa M Real, Ron Pedersen, Qi Shen, Lisa Marshall, Gaston Solano, Cecilia Elena Borlenghi, Rodolfo Pardo Hidalgo
BACKGROUND: Biologic agents may induce immune responses that could impact drug action. OBJECTIVES: The aims of this study were to assess antidrug antibodies (ADAs) in patients with rheumatoid arthritis (RA) from Argentina treated with etanercept, adalimumab, or infliximab at a single visit and correlate it with efficacy outcomes. METHODS: In this subset analysis of a noninterventional, multinational, cross-sectional study (NCT01981473), adult patients with RA treated continuously for 6 to 24 months with etanercept, adalimumab, or infliximab were evaluated for ADAs and trough drug concentrations of 2 days or less prior to the next scheduled dose...
December 12, 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/29224935/infliximab-for-the-treatment-of-refractory-kawasaki-disease-a-nationwide-survey-in-japan
#2
Hiroshi Masuda, Tohru Kobayashi, Akira Hachiya, Yasutaka Nakashima, Hiroyuki Shimizu, Tomo Nozawa, Yoshihito Ogihara, Shuichi Ito, Shinichi Takatsuki, Nobuyuki Katsumata, Yasuo Suzuki, Satoshi Takenaka, Keiichi Hirono, Tomio Kobayashi, Hiroshi Suzuki, Eisuke Suganuma, Kei Takahashi, Tsutomu Saji
OBJECTIVE: To assess the safety and efficacy of infliximab (IFX) for the treatment of patients with Kawasaki disease (KD). STUDY DESIGN: This was a nationwide survey of 274 Japanese institutions exploring how IFX was used to treat patients with KD. The patients' sex, age, treatment course, pre- and post-IFX therapy blood test results, coronary artery lesions (CALs), and adverse events (AEs) were evaluated. RESULTS: We analyzed 434 patients with KD who received IFX between March 2005 and November 2014...
December 7, 2017: Journal of Pediatrics
https://www.readbyqxmd.com/read/29215050/tumor-necrosis-factor-alpha-regulates-photoreceptor-cell-autophagy-after-retinal-detachment
#3
Jia Xie, Ruilin Zhu, Yuan Peng, Wenna Gao, Jiantong Du, Liang Zhao, Ying Chi, Liu Yang
Photoreceptor cell death is the ultimate process underlying many retinal diseases, including retinal detachment (RD). Both autophagy and inflammatory factors, such as tumor necrosis factor-alpha (TNF-α), participate in photoreceptor cell death after RD. In this study, we examined whether TNF-α inhibition would impact the autophagy of photoreceptors and reduce the death of photoreceptors after retinal detachment (RD). RD models were created in C57BL/6J mice by a subretinal injection of 1% hyaluronic acid. The TNF-α inhibitor infliximab was administered via intraperitoneal injection two hours before RD...
December 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29205444/switching-from-infliximab-innovator-to-biosimilar-in-patients-with-inflammatory-bowel-disease-a-12-month-multicentre-observational-prospective-cohort-study
#4
E M H Schmitz, P J Boekema, J W A Straathof, D C van Renswouw, L Brunsveld, V Scharnhorst, M E C van de Poll, M A C Broeren, L J J Derijks
BACKGROUND: Infliximab biosimilars have become available for treatment of inflammatory bowel disease (IBD). However, data showing long-term safety and effectiveness of biosimilars in IBD patients are limited. AIM: To study prospectively the switch from infliximab innovator to biosimilar in an IBD cohort with 12 months follow-up to evaluate safety and effectiveness. METHODS: Adult IBD patients from two hospitals treated with infliximab innovator (Remicade; Janssen Biotech,  Horsham ,  Pennsylvania, USA) were switched to infliximab biosimilar (Inflectra; Hospira, Lake Forest, Illinois, USA) as part of routine care, but in a controlled setting...
December 5, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29200248/detection-of-anti-infliximab-antibodies-in-slovak-ibd-patients-and-its-costs-saving-effect
#5
(no author information available yet)
OBJECTIVE: Management chronic inflammatory bowel disease (IBD) patients is associated with diagnosis, targeted treatment and and individual approach. There is a group of patients which loss the response to the biologic treatment caused by insufficient levels of biologics or positive antibodies against these drugs. This study was aimed to determine the prevalence of patients with positive antibodies against the biological treatment and the costs saving probabilities of the antibodies detection during the treatment...
November 4, 2017: Neuro Endocrinology Letters
https://www.readbyqxmd.com/read/29200097/external-evaluation-of-population-pharmacokinetic-models-of-infliximab-in-inflammatory-bowel-disease-patients
#6
Eugènia Santacana, Lorena Rodríguez-Alonso, Ariadna Padullés, Jordi Guardiola, Francisco Rodríguez-Moranta, Katja Serra, Jordi Bas, Francisco Morandeira, Helena Colom, Núria Padullés
BACKGROUND: Infliximab (IFX) trough levels vary markedly between patients with inflammatory bowel disease (IBD), which is important for clinical response. The aim of this study was to evaluate the performance of previously developed population pharmacokinetic models in IBD patients for dose individualization for Crohn's disease and ulcerative colitis in our clinical setting. METHODS: The authors collected 370 trough levels prospectively from 100 adult IBD patients who were undergoing IFX treatment between July 2013 and August 2016...
December 1, 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/29199203/hemophagocytic-syndrome-complicated-with-dermatomyositis-controlled-successfully-with-infliximab-and-conventional-therapies
#7
Yoji Komiya, Tetsuya Saito, Fumitaka Mizoguchi, Hitoshi Kohsaka
A 57-year-old woman was admitted to our hospital because of a high fever, anemia, and hyperferritinemia. Since a bone marrow examination revealed hemophagocytosis, she was diagnosed with hemophagocytic syndrome (HPS). During treatment of HPS, a heliotrope rash and Gottron's sign appeared with elevated levels of serum aldolase. She also developed heart failure. She was diagnosed with dermatomyositis (DM) and associated myocarditis. Although the administration of glucocorticoids, calcineurin inhibitors, intravenous immunoglobulins, and etoposide ameliorated the clinical findings of DM and cytopenia, the fever and hyperferritinemia remained...
2017: Internal Medicine
https://www.readbyqxmd.com/read/29189869/-acute-severe-ulcerative-colitis-treated-with-accelerated-infliximab-induction-case-report
#8
Daniela Fluxá, Lilian Flores, Udo Kronberg, Mauricio Moreno, Carolina Figueroa, Patricio Ibáñez, Jaime Lubascher, Daniela Simian, Rodrigo Quera
Acute severe ulcerative colitis (ASUC) is a potentially life-threatening condition that requires early recognition, hospitalization and adequate treatment. Currently, the use of infliximab in ulcerative colitis (UC) is recommended in the case of severe disease refractory to corticosteroids, once that superimposed bacterial or viral infections (such as cytomegalovirus or Clostridium difficile) have been excluded. However, conventional weight-based regimens of infliximab might be insufficient for patients with ASUC...
August 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/29185966/the-prevalence-and-clinical-effect-of-immunogenicity-of-tnf-%C3%AE-blockers-in-patients-with-axial-spondyloarthritis
#9
Gil Bornstein, Merav Lidar, Pnina Langevitz, Alexander Fardman, Ilan Ben-Zvi, Chagai Grossman
OBJECTIVES: To evaluate the prevalence of immunogenicity of TNF-α blockers in axial spondyloarthritis (SpA) patients and to assess the effect of immunogenicity on drug levels and clinical response. METHPDS: Patients with axial SpA treated with either infliximab (INF), adalimumab (ADA) or etanercept (ETN) were recruited to our observational cross-sectional study. Demographic and clinical data were collected and disease activity scores were assessed. Drug trough levels and anti-drug antibodies were measured in serum samples and collected before the next administration...
November 28, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29172974/following-the-biosimilar-breadcrumbs-when-health-systems-and-manufacturers-approach-forks-in-the-road
#10
Sonia T Oskouei
Over 2 years have passed since the first biosimilar was approved for use in the United States. Despite a relatively slow start, biosimilar activity has significantly increased in recent months. Biologics are the most expensive drug category in the United States, costing patients hundreds or even thousands of dollars per year. Biosimilars have the potential to significantly decrease cost of care, increase access, and improve patient outcomes. In order to realize the potential savings, biosimilar manufacturers, health care providers, and payers must develop strategies to navigate the challenging health care environment and understand where and how biosimilars bring the most value to patients...
December 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29171305/serum-interleukin-6-level-is-associated-with-response-to-infliximab-in-ulcerative-colitis
#11
Yu Nishida, Shuhei Hosomi, Kenji Watanabe, Kimihiko Watanabe, Tomomi Yukawa, Koji Otani, Yasuaki Nagami, Fumio Tanaka, Koichi Taira, Noriko Kamata, Hirokazu Yamagami, Tetsuya Tanigawa, Toshio Watanabe, Yasuhiro Fujiwara
OBJECTIVES: Infliximab is effective in patients with ulcerative colitis (UC); however, one-third of patients do not respond and require additional therapies such as other biologic agents. Therefore, the aim of this study was to analyze the association between pro-inflammatory molecules and clinical efficacy to elucidate possible mechanisms for the non-response to infliximab to aid in treatment selection. MATERIALS AND METHOD: Patients with moderate-to-severe active UC receiving infliximab in our hospital between 2010 and 2016 for whom pre-treatment serum samples were available were retrospectively evaluated...
November 24, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/29165430/subcutaneous-administration-of-infliximab-attenuated-silica-induced-lung-fibrosis
#12
Hua Zhang, Jun-Na Sui, Lei Gao, Jian Guo
OBJECTIVES: To investigate the influence of the anti-tumor necrosis factor-α infliximab (IFX) in the case of rats with silicosis. MATERIAL AND METHODS: Forty-eight Wistar rats were randomly divided into 3 groups. The study group (N = 16) - silicosis was induced by intratracheal instillation of 50 mg silica on day 1, and IFX was subcutaneously administered at a dose of 15 mg/kg of body weight from day 2 to day 6, the vehicle group (N = 16) - silica used as the study group but without IFX, the sham group (N = 16) - 1 ml of saline was intratracheal-used...
November 21, 2017: International Journal of Occupational Medicine and Environmental Health
https://www.readbyqxmd.com/read/29152405/association-of-mir-146-rs2910164-mir-196a-rs11614913-mir-221-rs113054794-and-mir-224-rs188519172-polymorphisms-with-anti-tnf-treatment-response-in-a-greek-population-with-crohn-s-disease
#13
Ioannis Papaconstantinou, Christina Kapizioni, Evangelia Legaki, Elena Xourgia, George Karamanolis, Antonios Gklavas, Maria Gazouli
AIM: To investigate the correlation between rs2910164, rs11 614913, rs113054794, and rs188519172 polymorphisms and response to anti-TNF treatment in patients with Crohn's disease (CD). METHODS: One hundred seven patients with CD based on standard clinical, endoscopic, radiological, and pathological criteria were included in the study. They all received infliximab or adalimumab intravenously or subcutaneously at standard induction doses as per international guidelines...
November 6, 2017: World Journal of Gastrointestinal Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29145599/a-role-for-thiopurine-metabolites-in-the-synergism-between-thiopurines-and-infliximab-in-inflammatory-bowel-disease
#14
Ditte V Mogensen, Jørn Brynskov, Mark A Ainsworth, Jacob Nersting, Kjeld Schmiegelow, Casper Steenholdt
Background: Interactions between principal cytotoxic thiopurine metabolites, 6-thioguanine nucleotides (6-TGN), and infliximab (IFX) and anti-IFX antibodies (Abs) may contribute to higher effectiveness of IFX-thiopurine-combination therapy than monotherapies in inflammatory bowel disease. Methods: To examine if thiopurine metabolites influenced trough IFX and anti-IFX Abs, 89 patients previously assessed for anti-IFX Abs were included. To assess if IFX influenced thiopurine metabolites, 8 patients having responded to 12 weeks of intensified IFX at a constant thiopurine dosing were included...
November 14, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29142035/the-sex-influence-on-response-to-tumor-necrosis-factor-%C3%AE-inhibitors-and-remission-in-axial-spondyloarthritis
#15
Ennio Lubrano, Fabio Massimo Perrotta, Maria Manara, Salvatore D'Angelo, Olga Addimanda, Roberta Ramonda, Leonardo Punzi, Ignazio Olivieri, Carlo Salvarani, Antonio Marchesoni
OBJECTIVE: The aim of this study was to evaluate the influence of sex on response to treatment and disease remission in patients with axial spondyloarthritis (axSpA). METHODS: In this retrospective multicenter study, patients with axSpA, according to the Assessment of Spondyloarthritis international Society (ASAS) criteria for axSpA, and treated with adalimumab, etanercept, golimumab, or infliximab, were studied. We compared clinical characteristics, patient-reported outcomes, disease activity, function, and response to treatment in male and female patients with this disease...
November 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29140939/infliximab-therapeutic-drug-monitoring-changes-clinical-decisions-in-a-virtual-biologics-clinic-for-inflammatory-bowel-disease
#16
Christian P Selinger, Marco V Lenti, Tanya Clark, Helen Rafferty, David Gracie, Alexander C Ford, Anthony OʼConnor, Tariq Ahmad, P John Hamlin
BACKGROUND: Virtual biologics clinics are often used to review patients with inflammatory bowel disease receiving biological therapy, with decisions whether to continue, switch, or stop therapy made based on review of symptoms, disease history, and investigations. We aimed to investigate whether therapeutic drug monitoring of infliximab (IFX) trough levels and anti-drug antibodies influences decision making within a virtual biologics clinic. METHODS: For all patients with inflammatory bowel disease receiving IFX maintenance therapy, 2 decisions were recorded in a preset format...
December 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29124774/early-drug-and-anti-infliximab-antibody-levels-for-prediction-of-primary-nonresponse-to-infliximab-therapy
#17
H Bar-Yoseph, N Levhar, L Selinger, U Manor, M Yavzori, O Picard, E Fudim, U Kopylov, R Eliakim, S Ben-Horin, Y Chowers, B Ungar
BACKGROUND: Primary nonresponse, defined as lack of clinical benefit during the induction phase, occurs in up to 30% of IBD patients treated with infliximab. The mechanisms underlying primary nonresponse have not yet been clearly defined. AIM: To evaluate the association of early (week 2 and week 6) induction infliximab and anti-infliximab antibody levels with primary nonresponse. METHODS: A retrospective observational case-control study of inflammatory bowel disease patients treated with infliximab and followed at Sheba Medical Center between 2009 and 2016 was performed...
November 9, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29121178/exploration-of-predictive-biomarkers-of-early-infliximab-response-in-acute-severe-colitis-a-prospective-pilot-study
#18
Lauren Beswick, Ourania Rosella, Gennaro Rosella, Belinda Headon, Miles P Sparrow, Peter R Gibson, Daniel R van Langenberg
Background: Outcomes of acute severe ulcerative colitis (ASUC) appear dependent on early intervention with the first and/or further infliximab(IFX) doses, though parameters to guide decision-making remain uncertain. Aim: To assess whether serum/faecal IFX levels and inflammatory biomarkers early post-IFX dose can predict ASUC outcomes. Methods: This prospective pilot study consecutively recruited inpatients with steroid-refractory ASUC, who then received 1-3 IFX rescue doses (5mg/kg/dose) per treating clinician's discretion...
November 7, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29119722/c-reactive-protein-as-a-predictor-of-low-trough-infliximab-concentrations-in-patients-who-lose-response-to-infliximab
#19
Marie P Boyle, Alan C Moss, Aoibhlinn M O'Toole, Byron Vaughn, Adam S Cheifetz
BACKGROUND: Low serum infliximab (IFX) concentrations are associated with an increased risk of loss of response in IBD. Whether C-reactive protein (CRP) could be used to identify patients with low drug concentrations is unknown. The objective of this study was to evaluate the test characteristics of CRP in identifying low serum IFX concentrations. METHODS: We measured serum IFX concentrations and CRP levels in patients who experienced symptom deterioration while on IFX (reactive cohort)...
November 9, 2017: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/29104875/a-novel-system-for-the-quantification-of-the-adcc-activity-of-therapeutic-antibodies
#20
Christophe Lallemand, Feifei Liang, Flore Staub, Maud Simansour, Benoit Vallette, Lue Huang, Rosa Ferrando-Miguel, Michael G Tovey
Novel ADCC effector cells expressing the V-variant or F-variant of FcγRIIIa (CD16a) and firefly luciferase under the control of a chimeric promoter incorporating recognition sequences for the principal transcription factors involved in FcγRIIIa signal transduction, together with novel target cells overexpressing a constant high level of the specific antigen recognized by rituximab, trastuzumab, cetuximab, infliximab, adalimumab, or etanercept, confer improved sensitivity, specificity, and dynamic range in an ADCC assay relative to effector cells expressing a NFAT-regulated reporter gene and wild-type target cells...
2017: Journal of Immunology Research
keyword
keyword
53792
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"